Bridge expands China operations with new lab
This article was originally published in Scrip
Executive Summary
Bridge Laboratories is to start constructing a second Chinese research facility in Beijing in the fourth quarter of this year. The 150,000 sq ft building in the city's Zhongguancun Life Science Park is due for completion, in compliance withUS and international regulatory standards, in the fourth quarter of next year . It will provide a range of preclinical contract services, in areas including toxicology, immunology, vaccines and bioanalyis.. The facility will quadruple the US contract research firm's laboratory space in China, it says.
You may also be interested in...
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Bayer won’t split, for now; Pfizer’s next-gen ADC pipeline; oncology dominates investment but other areas grow; goodbye NASH, hello MASH; and BMS’s CEO gives his views on India.